2020
Monitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment
Kelly CR, Laine LA, Wu GD. Monitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment. Gastroenterology 2020, 159: 2004-2006. PMID: 32841646, PMCID: PMC7443160, DOI: 10.1053/j.gastro.2020.08.039.Commentaries, Editorials and LettersMeSH KeywordsClostridium InfectionsCOVID-19Donor SelectionEscherichia coliEscherichia coli InfectionsFecal Microbiota TransplantationFecesHumansPractice Guidelines as TopicRegistriesTherapies, InvestigationalUnited StatesUnited States Food and Drug AdministrationConceptsTransplantation practice
2006
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiology And Drug Safety 2006, 15: 213-220. PMID: 16456879, DOI: 10.1002/pds.1207.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsAlanine TransaminaseAnti-Inflammatory Agents, Non-SteroidalArchivesBenzophenonesBiomarkersBromobenzenesChemical and Drug Induced Liver InjuryHumansLiverPhenylacetatesPropionatesRandomized Controlled Trials as TopicUnited StatesUnited States Food and Drug AdministrationConceptsAcute liver failureNonsteroidal anti-inflammatory drugsSerious hepatotoxicityLiver failureRisk of ALFSystematic reviewDifferent nonsteroidal anti-inflammatory drugsCommon adverse eventsHepatic enzyme elevationFlu-like symptomsDrug-induced hepatotoxicityAnti-inflammatory drugsClinical trial dataSymptomatic hepatitisALT elevationElevated transaminasesAdverse eventsEnzyme elevationDrug withdrawalHepatocellular jaundiceRare caseMedWatch systemDrug AdministrationHepatotoxicityTrial data